(AMT)

REITs finished the first quarter of 2025 in the red (-3.36%) with a brutal -4.92% average total return in March. Large cap (-2.04%) and mid cap REITs (-2.63%) saw modest losses, but small caps (-4.16%...

uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volat...

US equity markets steadied this past week while bond markets rallied as investors parsed a surprisingly solid slate of economic data and a decent start to corporate earnings season. Early week gains w...

Reflecting on past financial losses, I emphasize the importance of diversification to mitigate risks, as exemplified by my own experience with real estate investments. I advocate for a diversified inv...

uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operat...

REITs are not as heavily impacted by the trade war. Many are strongly outperforming in this environment. I present three safe havens that should thrive, regardless of what happens next with this trade...

While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.

For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.

MarketBeat has many tools, including the Top Rated Dividend Stocks screener. It ranks the top-100 dividend-paying stocks according to analysts' sentiment, giving a 4.00 to those with 100% Buy ratings ...

AMT's subsidiary CoreSite acquires Denver Gas & Electric Building to further expand its Denver market presence.